Rationale and design of the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF)

Faiez Zannad, John McMurray, Helmut Drexler, Henry Krum, Dirk Jan van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent, Bertram Pitt

Research output: Contribution to journalArticleResearchpeer-review

62 Citations (Scopus)

Abstract

Approximately 3100 patients with ejection fraction =30 and estimated glomerular filtration rate =30 mL/min/1.73 m2 will be recruited. Patients are randomized 1:1 to double-blind eplerenone or placebo in addition to standard chronic HF therapy. Doses are adjusted from 25 mg every other day to 50 mg daily, depending on serum potassium. The primary endpoint is a composite of time to cardiovascular death or first hospital admission for worsening HF, whichever occurs first.
Original languageEnglish
Pages (from-to)617 - 622
Number of pages6
JournalEuropean Journal of Heart Failure
Volume12
DOIs
Publication statusPublished - 2010

Cite this

Zannad, F., McMurray, J., Drexler, H., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., & Pitt, B. (2010). Rationale and design of the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). European Journal of Heart Failure, 12, 617 - 622. https://doi.org/10.1093/eurjhf/hfq049